Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma
CONCLUSION: Approximately 15% of the Korean patients treated with bortezomib experienced severe CVAEs. Thus, patients, especially those with identified risk factors, should be closely monitored for CVAE symptoms during bortezomib treatment.PMID:38485811 | DOI:10.1007/s44313-024-00004-y (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Bitna Jang Jonghyun Jeong Kyu-Nam Heo Youngil Koh Ju-Yeun Lee Source Type: research
Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma
CONCLUSION: Approximately 15% of the Korean patients treated with bortezomib experienced severe CVAEs. Thus, patients, especially those with identified risk factors, should be closely monitored for CVAE symptoms during bortezomib treatment.PMID:38485811 | PMC:PMC10903519 | DOI:10.1007/s44313-024-00004-y (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Bitna Jang Jonghyun Jeong Kyu-Nam Heo Youngil Koh Ju-Yeun Lee Source Type: research
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines
CONCLUSIONS: Taken together, these studies suggest that CCR1 expression may be associated with decreased response to bortezomib in MM cell lines.PMID:38479337 | DOI:10.1016/j.leukres.2024.107469 (Source: Cell Research)
Source: Cell Research - March 13, 2024 Category: Cytology Authors: Mara N Zeissig Duncan R Hewett Krzysztof M Mrozik Vasilios Panagopoulos Craig T Wallington-Gates Andrew Spencer Sandra M Dold Monika Engelhardt Kate Vandyke Andrew C W Zannettino Source Type: research
Therapeutic Effect and Adverse Event Rate of Different Treatment Methods in Patients with Multiple Myeloma and Renal Insufficiency
CONCLUSION: The application of the BCD regimen in the treatment of MM has shown significant efficiency, effectively alleviating clinical symptoms with fewer adverse reactions and high safety.PMID:38467118 | DOI:10.1159/000536170 (Source: Herpes)
Source: Herpes - March 11, 2024 Category: Infectious Diseases Authors: Lijuan Cui Jing Ning Rui Yang Hainan Wang Source Type: research
Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19
CONCLUSION: DAP inhibited the proliferation, migration, and invasion and promoted the apoptosis of MM cells. Mechanistically, the RPS19 expression was significantly decreased in DAPtreated cells. This research provides a potential therapeutic drug for MM therapy.PMID:38454765 | DOI:10.2174/0113862073283460240129104114 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - March 8, 2024 Category: Chemistry Authors: Yijun Zhuang Yin Zhang Caiyun Chen Jincheng Chen Qiuxia Xu Peihong Wang Source Type: research
Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19
CONCLUSION: DAP inhibited the proliferation, migration, and invasion and promoted the apoptosis of MM cells. Mechanistically, the RPS19 expression was significantly decreased in DAPtreated cells. This research provides a potential therapeutic drug for MM therapy.PMID:38454765 | DOI:10.2174/0113862073283460240129104114 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - March 8, 2024 Category: Chemistry Authors: Yijun Zhuang Yin Zhang Caiyun Chen Jincheng Chen Qiuxia Xu Peihong Wang Source Type: research
Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19
CONCLUSION: DAP inhibited the proliferation, migration, and invasion and promoted the apoptosis of MM cells. Mechanistically, the RPS19 expression was significantly decreased in DAPtreated cells. This research provides a potential therapeutic drug for MM therapy.PMID:38454765 | DOI:10.2174/0113862073283460240129104114 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - March 8, 2024 Category: Chemistry Authors: Yijun Zhuang Yin Zhang Caiyun Chen Jincheng Chen Qiuxia Xu Peihong Wang Source Type: research
Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19
CONCLUSION: DAP inhibited the proliferation, migration, and invasion and promoted the apoptosis of MM cells. Mechanistically, the RPS19 expression was significantly decreased in DAPtreated cells. This research provides a potential therapeutic drug for MM therapy.PMID:38454765 | DOI:10.2174/0113862073283460240129104114 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - March 8, 2024 Category: Chemistry Authors: Yijun Zhuang Yin Zhang Caiyun Chen Jincheng Chen Qiuxia Xu Peihong Wang Source Type: research
Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19
CONCLUSION: DAP inhibited the proliferation, migration, and invasion and promoted the apoptosis of MM cells. Mechanistically, the RPS19 expression was significantly decreased in DAPtreated cells. This research provides a potential therapeutic drug for MM therapy.PMID:38454765 | DOI:10.2174/0113862073283460240129104114 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - March 8, 2024 Category: Chemistry Authors: Yijun Zhuang Yin Zhang Caiyun Chen Jincheng Chen Qiuxia Xu Peihong Wang Source Type: research
